![Second-Line Treatment Landscape for Advanced HCC](http://media.vumedi.com/thumbs/channel_logo/2022/3/47d2618e-3670-49ed-9fb8-a81950ef883f.png.200x0_q85.png)
Second-Line Treatment Landscape for Advanced HCC
ASCO 2022 IMMUTACE - A Biomarker-Orientated Phase II, Single-Arm, Open-Label AIO Study of Transarterial Chemoembolization + Nivo Performed for Intermediate-Stage HCC: Updated Efficacy Results
By
ASCO 2022 Conference Coverage
FEATURING
Arndt Vogel
By
ASCO 2022 Conference Coverage
FEATURING
Arndt Vogel
Login to view comments.
Click here to Login
Second-Line Treatment Landscape for Advanced HCC